¶ Lucia Zhang
Lucia Zhang is a Canadian regulatory official based in Ottawa, Ontario. She is a Senior Clinical Evaluator at Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD).[1][2]
She is a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and the American Society for Bone and Mineral Research (ASBMR).[3]
¶ History
Zhang's hometown is Edmonton, Alberta.[4]
¶ Education
Zhang attended the University of Toronto from September 2009 to June 2013 for her Bachelor of Science in Pharmacology and Toxicology, and September 2013 to June 2018 for her Doctor of Philosophy in Pharmacology.[1:1] She worked as as Summer Intern at National Research Council Canada (NRC) from May to August 2010. She served in several roles at the Pharmacology and Toxicology Students' Association (PTSA) and the Pharmacology Graduate Students' Association (PGSA).[5]
Zhang conducted research in the Grynpas Lab at the Lunenfeld-Tanenbaum Research Institute.[6] She volunteered at Toronto Western Hospital from September 2012 to June 2013.
¶ Career
Zhang began work at Health Canada as a Clinical Evaluator in June 2018.
¶ COVID-19
Zhang participated in the 14th Workshop on Recent Issues in Bioanalysis from June 15-29, 2020. The conference was partnered with the Future Science Group (FSG).
On February 2021, the journal Bioanalysis published a paper co-authored by Zhang titled "2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 – Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)".[7] Among her co-authors are representatives from:
- AbbVie
- Ablynx
- AstraZeneca
- BioAgilytix
- Biogen
- BioMarin
- Bluebird Bio
- BRI
- Canadian Forum for Analytical and Bioanalytical Sciences (CFABS)
- CRISPR Therapeutics
- Food and Drug Administration (FDA)
- GlaxoSmithKline
- Hexal
- Immunologix Labs
- Intellia Therapeutics
- Janssen
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Merck
- Ministry of Health, Labour and Welfare of Japan (MHLW)
- Navigate BioPharma
- Norwegian Medicines Agency
- Novartis
- Novo Nordisk
- Pfizer
- PPD
- Regeneron Pharmaceuticals
- Roche
- Sangamo Therapeutics
- Takeda Pharmaceuticals
Zhang was promoted to Senior Clinical Evaluator in March 2021.
¶ Activities
Zhang has participated in research funded by the Canadian Institutes of Health Research (CIHR).[8]
¶ External links
Lucia Zhang. LinkedIn. Retrieved May 27, 2023, from http://archive.today/2023.05.27-053527/https://www.linkedin.com/in/lucia-zhang-53143226/ ↩︎ ↩︎
Lucia Zhang · Health Canada · Clinical Evaluator. OpenGovCa. Retrieved May 27, 2023, from https://web.archive.org/web/20230527053643/https://opengovca.com/employee/lucia-zhang ↩︎
Organizations | Lucia Zhang. LinkedIn. Retrieved May 27, 2023, from https://www.linkedin.com/in/lucia-zhang-53143226/details/organizations/ ↩︎
Lucia Zhang - Pharmacology and Toxicology. University of Toronto. Retrieved May 27, 2023, from https://web.archive.org/web/20230527055815/https://glse.utoronto.ca/lucia-zhang-pharmacology-and-toxicology ↩︎
VIP 2018 Abstract Booklet. University of Toronto. Retrieved May 27, 2023, from https://web.archive.org/web/20230528054627/https://pharmtox.utoronto.ca/sites/default/files/VIP 2018 Booklet Final.pdf ↩︎
Lucia Zhang | Dr. Marc Grynpas. Lunenfeld-Tanenbaum Research Institute. Retrieved May 28, 2023, from http://archive.today/2023.05.28-053645/https://research.lunenfeld.ca/grynpas/Default.asp?page=lucia-zhang ↩︎
Corsaro, B., Yang, T.-Y., Murphy, R., Sonderegger, I., Exley, A., Bertholet, S., Dakappagari, N., Dessy, F., Garofolo, F., Kierstead, L., Koch, H., Sarikonda, G., Savoie, N., Siggers, R., Solstad, T., Lu, Y., Milton, M., Marshall, J.-C., DelCarpini, J., & Gorovits, B. (2021). 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis, 13(6), 415–463. https://doi.org/10.4155/bio-2021-0007 ↩︎
Zhang, L., Sugamori, K. S., Claridge, C., dela Cruz, A., Grynpas, M. D., & Mitchell, J. (2017). Overexpression of GαS in Murine Osteoblasts In Vivo Leads to Increased Bone Mass and Decreased Bone Quality. Journal of Bone and Mineral Research, 32(11), 2171–2181. https://doi.org/10.1002/jbmr.3223 ↩︎